Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17315776 | 0.86 | GRIN2B (0.34) | GRIN2BCA2 | |
| SCHEMBL17315780 | 0.86 | GRIN2B (0.34) | GRIN2BCA2 | |
| SCHEMBL17315775 | 0.86 | HTT (0.37) | GRIN2B | |
| SCHEMBL17315783 | 0.75 | LMNA (0.41) | GRIN2BCA2 | |
| SCHEMBL17583193 | 0.75 | CA2 (0.41) | GRIN2BCA2CA1 | |
| SCHEMBL16665045 | 0.73 | MEN1 (0.32) | — | |
| SCHEMBL17315794 | 0.71 | GRIN2B (0.37) | GRIN2B | |
| SCHEMBL17325423 | 0.71 | GRIN2B (0.37) | GRIN2B | |
| SCHEMBL17583209 | 0.68 | CA2 (0.39) | CA2CA1 | |
| SCHEMBL20638849 | 0.67 | GRIN2B (0.33) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152213-B1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2018-10-31 | — | — | EP | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| EP-3152213-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | Rugen Holdings (Cayman) Limited (KY) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187845-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187845-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | GRIN1, GRIN2A, GRIN2B | GRIN2B 3/4885CA2 3535/4885CA1 1780/4885 |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | GRIN2B 3/4885CA2 3535/4885CA1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.